Founded by Lux Capital in 2004, Lux Research helps leaders in business, finance, and government make informed, strategic decisions. Through its proprietary methodologies and global network of innovators, Lux Research uncovers opportunities and provides its readers with competitive advantages. Lux Research was acquired by Bregal Sagemount in 2017.
Nulla adipisicing do ut aliquip elit tempor fugiat. Mollit est exercitation excepteur ea consequat ullamco Lorem ex id. Ipsum nostrud Lorem dolor nisi do est in ex amet eu nostrud. Amet commodo consectetur enim nostrud dolore sint excepteur irure aliqua consectetur. Veniam occaecat et enim eiusmod qui fugiat eiusmod eiusmod laborum exercitation veniam ipsum velit. Ut veniam cupidatat ea tempor ad ad exercitation amet qui. Esse commodo sint deserunt ut elit minim sint. Amet laborum ut adipisicing minim sunt cillum anim in est ipsum aliquip anim in tempor pariatur.
Progressing Science Knowledge
Lux founded: 2004
Acquired: 2017
Lux Research
Similar companies
Hugging Face is on a mission to advance and democratize Natural Language Processing.
Infrastructure Computer Science
Progressing Science Knowledge
Increasing Productivity Efficiency
Lux investment: 2019
Clément Delangue
Julien Chaumond
Eikon Therapeutics is pioneering a new method of drug discovery based on tracking and measuring the movement of individual proteins in living cells.
Biology Biochemistry
Advancing Human Health
Progressing Science Knowledge
Lux investment: 2019
Eric Betzig
Robert Tjian
Luke Lavis
Xavier Darzacq
MosaicML improves efficiency of neural network training with algorithmic methods that deliver speed, boost quality and reduce cost.
Infrastructure Computer Science
Progressing Science Knowledge
Increasing Productivity Efficiency
Lux investment: 2021
Acquired by Databricks: 2023
Recursion Pharma is combining high-throughput experimental biology, bioinformatics, and machine learning to rapidly identify new indications for many known drugs and shelved assets. The company completed its IPO [NASDAQ: RXRX] in 2021.
Biology Biochemistry
Advancing Human Health
Progressing Science Knowledge
Lux investment: 2016
IPO: 2021
Chris Gibson, PhD
Blake Borgeson, PhD
Dean Li, PhD
Cajal Neuroscienceis a drug discovery company focused on neurodegenerative disease.
Biology Biochemistry
Advancing Human Health
Progressing Science Knowledge
Lux investment: 2020
Ian Peikon, PhD
Charles Zuker, PhD
Huda Zoghbi, MD
Tony Zador, MD, PhD
Rob Hershberg, MD, PhD
Andrew Dervan, MD